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ABSTRACT: Chondroitin sulfate proteoglycans inhibit regeneration, neuro-
protection, and plasticity following spinal cord injury. The development of a
second-generation chondroitinase ABC enzyme, capable of being secreted from
mammalian cells (mChABC), has facilitated the functional recovery of animals
following severe spinal trauma. The genetically modified enzyme has been shown
to efficiently break down the inhibitory extracellular matrix surrounding cells at
the site of injury, while facilitating cellular integration and axonal growth.
However, the activity profile of the enzyme in relation to the original bacterial
chondroitinase (bChABC) has not been determined. Here, we characterize the
activity profile of mChABC and compare it to bChABC, both enzymes having
been maintained under physiologically relevant conditions for the duration of the
experiment. We show that this genetically modified enzyme can be secreted
reliably and robustly in high yields from a mammalian cell line. The modifications
made to the cDNA of the enzyme have not altered the functional activity of
mChABC compared to bChABC, ensuring that it has optimal activity on chondroitin sulfate-A, with an optimal pH at 8.0 and
temperature at 37 °C. However, mChABC shows superior thermostability compared to bChABC, ensuring that the recombinant
enzyme operates with enhanced activity over a variety of physiologically relevant substrates and temperatures compared to the
widely used bacterial alternative without substantially altering its kinetic output. The determination that mChABC can function with
greater robustness under physiological conditions than bChABC is an important step in the further development of this auspicious
treatment strategy toward a clinical application.
■ INTRODUCTION
Promoting functional and anatomical regeneration following
spinal cord injury (SCI) is therapeutically challenging. A major
obstacle to any form of recovery is the inhibitory environment
that develops around the lesion site, dominated by the
presence of chondroitin sulfate proteoglycans.1−3 The bacterial
enzyme chondroitinase ABC (bChABC) acts by cleaving the
chondroitin sulfate-glycosaminoglycan (CS-GAG) chains into
their component disaccharides and subsequently removing
what is considered to be the major inhibitory component of
these macromolecules.4−7 Treatment using this enzyme
(originally isolated fromProteus vulgaris) has been successful
at promoting plasticity and regeneration in vivo and in vitro
following experimental SCI in a number of different
models.8−17 However, several factors limit the clinical use of
the enzyme in vivo. For example, bChABC is temperature-
sensitive, losing most activity within 3 to 10 days at 37 °C.18,19
For the more severe SCIs, a single bolus injection of the
enzyme is not sufficient to yield functional recovery,20−22 and a
more invasive treatment or repeated administration is required,
such as intrathecal infusion or secretion of the enzyme from an
implanted biomaterial.23−26
Gene therapy has often been used to facilitate the
experimental sustained delivery of therapeutic molecules
through in vivo or ex vivo strategies. Cafferty et al.27
demonstrated these techniques in vivo through the transgenic
expression of bChABC cDNA in mouse reactive astrocytes
under the GFAP promoter, facilitating the decrease of CS-
GAGs at the site of SCI. However, the N-glycosylation system
in eukaryotes has limited the secretion of the bacterial enzyme
in mammalian cells.27 A recombinant form of bChABC capable
of being transduced and secreted in an active form from
mammalian cells (mChABC) has been developed through the
mutagenesis of key N-glycosylation sites on the molecule.28,29
Recently, it has been shown that targeting this mChABC
construct to axons can promote neurite extension in vitro.30
Using a lenti-viral version of mChABC, we have shown that
enzyme-transduced Schwann cells are able to migrate and
intermingle within astrocytic boundaries, facilitating neurite
outgrowth in vitro and in vivo.29 Following acute lenti-viral
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transduction into the injured spinal cord, mChABC was shown
to be secreted, active, and able to produce functional sprouting
and motor recovery up to 10 weeks following trauma in
vivo.31,32 In combination with the development of viral
technology, mChABC has recently been expressed successfully
in an immune-evasive regulatable adeno-associated viral vector
under doxycycline induction.32 This provides an important
pathway for the potential translation of ChABC in gene
therapy. However, neither the biochemical characteristics of
mChABC under physiologically relevant conditions nor the
relationship it has with those of the commercial bChABC has
been determined. This is despite in vitro and in vivo evidence
that the recombinant enzyme may be more effective than
bChABC.29
It is important to assess the characteristics of mChABC to
determine if it operates effectively in conditions likely to be
experienced within the human body. These data may impact
the development of the mChABC construct for clinical
treatments. Furthermore, it is important to determine if the
modifications made to the recombinant enzyme have caused
alterations in its potential activity and effectiveness. Here, we
use transfection of a plasmid-mChABC to show the ease of
enzyme expression in, and secretion from, mammalian cells.
We report the optimal biochemical conditions and enzyme
kinetics for the secreted mChABC enzyme under physiolog-
ically relevant conditions and demonstrate that the recombi-
nant enzyme has superior functionality than bChABC due to
increased thermostability.
■ RESULTS AND DISCUSSION
Transfection of HEK293 Cells Yields High Quantities
of Thermostable mChABC. In order to assess the activity of
mChABC, HEK293 cells were transfected with the plasmid
mChABC (p-mChABC) construct through nucleofection
(Supporting Information Figure S1A−C). The concentrated
lysate was collected over 24 h following transfection and
assessed for mChABC activity using the cetylpyridinium
chloride (CPC) turbidity assay. A population of 2 × 106
cells transfected with p-mChABC consistently produced a yield
of 0.0002 μmol/min active enzyme as compared to control
populations, which yielded no such activity (Figure 1A). The
day of collection following transfection did not affect the
amount of the active enzyme produced [F(1,4) = 0.0163, p =
0.905, two-way ANOVA with post-hoc Turkey], suggesting
that the cells can regularly secrete similar amounts of the
molecule over time. To assess the stability of the enzyme,
0.0001 μmol/min of mChABC and bChABC was incubated at
37 °C for 6 days with activity measured daily. The secreted
mChABC was shown to have superior thermostability in
culture medium compared to the commercially available
bChABC, remaining at a plateau of activity for 5 rather than
2 days and exhibiting less loss of total activity over time
[Figure 1B; F(12,36) = 19.2, P < 0.0001, two-way ANOVA
post-hoc Turkey]. These data demonstrate that biologically
active mChABC is expressed and secreted from transfected
cells with high stability.
Biochemical Characterization of mChABC Activity.
Having established mChABC expression in HEK293 cells, the
optimal biochemical conditions to achieve maximal activity of
the mammalian enzyme were determined and assessed against
Figure 1. Amount and stability of active mChABC secreted by HEK293 cells. (A) Average amount of active mChABC secreted from HEK293 over
a 24 h period for 2 consecutive days following transfection (N = 3 from independent cell batches). (B) Stability of 0.0001 μmol/min mChABC
over a period of 6 days at 37 °C (N = 3 from independent cell batches). For both panels, data show means ± SD.
Table 1. Activity of Commercial bChABC and mChABC Acting on GAG Substratesa
substrate average MW (kDa) control (μmol min−1 mg−1) mChABC (μmol min−1 mg−1) bChABC (μmol min−1 mg−1)
CS-A from bovine trachea 12 0.0558 ± 0.000185 4.69 ± 0.00614 3.35 ± 0.00596
DS from porcine intestinal mucosa 16 0.0264 ± 0.000573 2.57 ± 0.0086 2.23 ± 0.00167
CS-C from shark cartilage 35 0.0147 ± 0.00019 3.57 ± 0.00436 2.95 ± 0.00334
Hyaluronan 215 0.0117 ± 0.000173 0.444 ± 0.00131 0.429 ± 0.0014
aEnzyme activity measured as U/mg of protein (μmol min−1 mg−1). Values show means ± SD and shown to three significant figures. The
experiment was conducted at pH 8 and 37 °C (N = 3 for each condition from independent cell batches). Sigma bChABC was preincubated at 37
°C for 48 h prior to assessment. MW = molecular weight.
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the commercially available bChABC. These parameters
included substrate specificity, pH, temperature, and thermo-
stability. To ensure accuracy when comparing the mChABC
and bChABC, the commercial enzyme was placed under the
same conditions as the recombinant enzyme for the same
length of time [Dulbecco’s modified Eagle’s medium (DMEM)
with sodium pyruvate and ITS+, at 37 °C for 24 h, centrifuged,
EDTA-free protease inhibitor cocktail added, concentrated,
and quantity of the active enzyme assessed through the CPC
turbidity assay].
Optimal Substrate. Concentrations of 0.5 μg/μL active
mChABC and bChABC were determined using the CPC
turbidity assay and used to assess the activity of the ChABCs
on CS-A, -C, DS, and HA (Table 1; Supporting Information
Figure S2). These data showed that both the specific ChABC
used [F(2,24) = 555,836, P < 0.0001, two-way ANOVA with
post-hoc Bonferroni] and the substrate under consideration
[F(3,24) = 205,278, P < 0.0001, two-way ANOVA with post-
hoc Bonferroni] affected the degree of enzyme activity.
Interestingly, both mChABC and bChABC exhibited minimal
levels of activity on HA at pH 8.0, showing no difference from
control (P = ns; Table 1). However, mChABC showed activity
on CS-A, CS-C, and DS, which was ∼25% higher than that
achieved with the bChABC (Table 1; P < 0.0001 in all
comparisons). Both mChABC and bChABC showed an ∼25%
decrease in activity using CS-C and ∼50% reduction with DS
substrates as compared to CS-A (Table 1),6,33,34 clearly
establishing the latter as the optimal substrate. These data
confirm that the modifications to mChABC have not altered
the enzyme substrate binding properties, explaining why it has
effects similar to the commercial enzyme in vivo. However,
mChABC shows greater activity than the bacterial enzyme
under the same conditions.
Optimal pH. The pH range at which the enzymes maximally
operate was evaluated using both CS-A and HA as substrates
and the relative activity reported as compared to the maximum
obtained. mChABC and bChABC showed activity greater than
the control in all experimental conditions (Figure 2). Both
enzymes exhibited a relatively narrow pH-activity profile of
±0.5 pH around the optimum pH 8.0 on CS-A [Figure 2A;
F(4,30) = 446.7, P < 0.0001, two-way ANOVA with post-hoc
Turkey]. However, mChABC showed ∼25% greater activity
compared to the bChABC over this pH range [F(2,30) =
591.3, P < 0.0001, two-way ANOVA with post-hoc Turkey].
These data again suggest that the engineered mChABC
enzyme functions more effectively than the commercial
alternative. The optimum activity on HA for both ChABCs
occurred at pH 6.0 [Figure 2B; F(4,30) = 345.2, P < 0.0001,
two-way ANOVA with post-hoc Turkey].4,6,33−35 Both
mChABC and bChABC were relatively active over a wider
pH range than displayed on CS-A (pH 5−8), although enzyme
activity was substantially reduced (Figure 2B; Table 1).
Interestingly, when outside the optimal pH range (and thus
under different conditions from those in Table 1), mChABC
showed increased activity on HA compared to bChABC [P <
0.0001; Figure 2B; F(2,30) = 1678, P < 0.0001, two-way
Figure 2. pH specificity of mChABC compared to bChABC. Effect of pH on enzyme activity when incubated with (A) CS-A and (B) hyaluronic
acid (HA). For both panels, data show means ± SD and N = 3 (from independent cell batches).
Figure 3. Temperature specificity of mChABC compared to bChABC. Effect of temperature on enzyme activity using CS-A at pH 8 over (A) a
temperature range, and preincubation of the enzyme at (B) 37 °C and (C) 50 °C to assess thermostability. For all panels, data show means ± SD
and N = 3 (from independent cell batches).
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ANOVA with post-hoc Turkey]. These data show that
mChABC may function better under the physiological
conditions of the mammalian body than bChABC. All
subsequent assays were performed at the optimized pH 8.0
on CS-A.
Optimal Temperature. We showed that both the specific
ChABC used [F(2,36) = 2468, P < 0.0001, two-way ANOVA
with post-hoc Turkey] and the temperature at which the assay
is conducted [F(5,36) = 596.1, P < 0.0001, two-way ANOVA
with post-hoc Turkey] affected enzyme activity (Figure 3).
Both mChABC and bChABC showed optimal activity at the
physiological temperature of 37 °C (Figure 3A). Furthermore,
the activity profile of the two enzymes over the temperature
range was similar with an ∼40% increase in relative activity
over 25−37 °C, and a rapid decline in activity as temperatures
increased. Indeed, the ChABC enzymes showed an ∼50% loss
in relative activity in temperatures exceeding 40 °C. However,
consistent with our previous data, mChABC showed an ∼25%
greater relative activity than bChABC across this temperature
range (Figure 3A; minimum P < 0.01). This is again indicative
of the greater activity and stability of the recombinant enzyme,
suggesting that it may be more effective than the commercial
alternative in vivo.
To determine if the rapid decline in mChABC and bChABC
relative activity at higher temperatures was caused by
irreversible denaturation, the enzymes were incubated for 5,
10, and 15 min at 37 or 50 °C and then transferred to 37 °C
for data acquisition (Figure 3B,C). Interestingly, data show
that mChABC was relatively stable at 37 °C, more so than
bChABC, the latter showing a gradual decline in relative
activity with continued incubation (Figure 3B; variation due to
the enzyme used F(2,18) = 14,404, P < 0.0001; variation due
to time F(2,18) = 17.02, P < 0.0001, two-way ANOVA with
post-hoc Turkey). The trends in data are also shown at 50 °C
[Figure 3C; variation due to the enzyme used F(2,18) = 203.1,
P < 0.0001; variation due to time F(2,18) = 61.93, P < 0.0001,
two-way ANOVA with post-hoc Turkey]. Under these
conditions, the relative activity of mChABC falls by ∼25%
for every 5 min of incubation. The decline in bChABC activity
is far more rapid with a ∼45% decrease for every 5 min of
incubation, occurring under minimal baseline conditions
following 15 min incubation (P = 0.9998; Figure 3C). These
data suggest that denaturation is a factor in ChABC activity at
temperatures above 40 °C and that mChABC is more
thermostable than the commercial enzyme at all physiologi-
cally relevant temperatures assessed.
mChABC Kinetic Activity. Kinetic parameters were
determined for the engineered mChABC enzyme and
compared to the commercial bChABC (Table 2). The kinetic
parameters used to characterize enzyme activity each showed
differences due to the enzyme used. This included the
concentration of the substrate leading to half-maximal velocity
[Km; F(2,21) = 471.5, P < 0.0001, one-way ANOVA with post-
hoc Turkey] the number of substrate molecules the enzyme
converts to product per unit time [kcat; F(2,21) = 13,428, P <
0.0001, one-way ANOVA with post-hoc Turkey]; and the
catalytic efficiency [kcat/Km; F(2,21) = 135.1, P < 0.0001, one-
way ANOVA with post-hoc Turkey]. mChABC showed a
decrease in CS-A binding affinity (Km) compared to bChABC
(Table 2). However, the engineered enzyme showed a large
increase (P < 0.0001) in values describing the catalytic center
of activity (kcat). This means that mChABC may bind with
slightly less frequency to the substrate than bChABC.
However, following binding, mChABC catabolizes the
molecule with greater frequency than bChABC. For this
reason, there is no significant difference between the catalytic
efficiency (kcat/Km) of mChABC and bChABC (P = 0.216;
Table 2), suggesting that the reaction rate of the enzymes is
similar under optimal conditions.
We have established the biochemical characteristics of a
mammalian-compatible ChABC in direct comparison with the
commercial bacterial alternative. We show that delivery of the
recombinant mChABC into mChABC leads to high expression
and secretion of the active enzyme in vitro. The resulting
mChABC produced was shown to have superior biological
activity on a variety of physiological substrates, while
maintaining the enzymes optimal temperature and pH range.
While the genetic alterations made to mChABC were shown to
modify individual components of the enzyme catalytic
reaction, ultimately its kinetic capacity is no different from
the commercially available bChABC. However, we demon-
strate that due to superior thermostability, mChABC has
significantly greater activity then bChABC under physiological
conditions, supporting its use in vivo and continued develop-
ment as a clinical treatment.
The large-scale expression and secretion of active mChABC
from cell lines has not previously been shown. We demonstrate
that mChABC is secreted in high yields in mChABC over
consecutive days under physiological conditions. Active
bacterial ChABC has been secreted from mChABC following
the removal of the hydrophobic leader sequence.36,37 However,
the yield of active ChABC in this form was modest in
comparison to that reported here.37 Similarly, chondroitinase
AC (ChAC) can be endogenously secreted in an active form
from mChABC in vitro and in vivo.38,39 Unfortunately, activity
characterization of ChAC showed only modest enzyme yield
and specific activities on both CS-A and CS-C40 in comparison
to the values, which we report for mChABC. Moreover, ChAC
does not act on DS, which is expressed in the spinal cord
following injury,41 reducing the enzyme’s effectiveness as a
potential SCI treatment. Importantly, we show activity of
mChABC is superior to bChABC and other known secreted
forms of chondroitinase on all sulfates (CS-A, DS, and CS-C),
which predominate in the normal and injured CNS.42 This
would suggest that the specific modifications made to
mChABC cDNA facilitate optimal enzyme secretion and
activity within physiological in vitro and in vivo conditions.
We demonstrate that mChABC operates optimally under
the same physiological temperature and pH profile as
bChABC.4,6,33−35 Moreover, the kinetic profile of mChABC
activity shows that the enzymes substrate binding affinity has
been reduced, but the catalytic activity of the enzyme has
Table 2. Kinetic Analysis of mChABC and Commercial
bChABCa






−0.0384 ± 0.147 0.163 ± 0.0372 −4.24
mChABC 0.527 ± 0.0523 46.1 ± 0.874 84.5
bChABC
(Sigma)
0.373 ± 0.0318 37.1 ± 0.544 99.4
aValues show means ± SD. Km and kcat are shown to three significant
figures and kcat/Km to 1 decimal place. N = 8 for each condition (from
independent cell batches).
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increased as compared to bChABC. This ensures that the
catalytic efficiency exhibited by mChABC is similar to the
commercial enzyme.4,6,33−35,43 However, we uniquely demon-
strate that the activity of mChABC significantly exceeded that
of the commercial bChABC under optimal physiological
conditions due to increased thermostability. mChABC is
stable in vitro over 3 day at 37 °C, far greater than 24 h
achieved by bChABC.18 The modifications made to mChABC
appear to achieve similar levels of thermostabilization as
yielded by those of trehalose.44 These data may explain why
the modified enzyme has functioned better than the bacterial
alternative in vivo31,32,45 and the increase in cellular integration
and neurite outgrowth caused by mChABC in vitro and in vivo
when compared to bChABC acting under the same
conditions.29 The increased thermostability exhibited by
mChABC further promotes the use of this second-generation
enzyme over the commercially available bChABC.
■ CONCLUSIONS
mChABC can be reliably and robustly produced from
mammalian cell lines. This modified enzyme operates with
the same efficiency, optimally under the same physiological
conditions, and upon identical substrates as the commercial
bacterial enzyme. However, the modified mChABC has
increased thermostability at physiologically relevant temper-
atures, increasing the enzyme functional output compared to
the widely used bChABC. These findings support the
development of mChABC as a treatment for SCI and other
pathological diseases as well as extending our knowledge
concerning the expression of prokaryotic genes in eukaryotes.
■ EXPERIMENTAL SECTION
Institutional ethical approval was not required for these
experiments, and the study was not preregistered. The
recombinant form of bChABC used in this study (mChABC)
was based on clone Y133 with mutations at N-glycosylation
sites Asn 675,282, 345, 515 (S-A), and 715. Please see the
study by Muir et al. for further details regarding the
modifications made.28,30
Cell Culture Reagents. DMEM with and without phenol
red and fetal calf serum (FCS) were purchased from Thermo
Fisher Scientific. Penicillin/streptomycin/fungizone (PSF;
2%), trypsin, and poly-D-lysine were purchased from Sigma,
while ITS+ (Insulin-transferrin-sodium selerite with bovine
serum albumin and linoleic acid; 1:100) was from BD
Bioscience. Bacterial chondroitinase ABC (Sigma) was used
in a buffer containing 50 mM Tris base and 50 mM sodium
acetate (pH 8.0; Sigma). Cell counts were conducted using a
Countess automated cell counter (Thermo Fisher Scientific).
Culture and Transfection of HEK293 Cells. Human
embryonic kidney (HEK293) cells were procured from frozen
stock populations, thawed, and grown in supplemented
DMEM [DMEM with 10% FCS, 2% penicillin/streptomy-
cin/amphotericin, bovine pituitary extract (Sigma, 10 μg/mL)]
at 37 °C with 7% CO2 and passaged at a ratio of 1:10 every 48
h (or when 70% confluent) using 0.1% trypsin to avoid
senescence and increased cell numbers. Stock populations were
validated from the producer prior to freezing and underwent
no more than 15 passages before being replaced with new
stock population. Flasks of cells were assigned to experimental
groups using simple randomization, and the experimenter was
blind to the treatment groups at all stages of the experiment
and analysis.
HEK293 cells were transfected with a Nucleofector (Lonza;
program A-23) using Cell Line Nucleofector Kit V (Lonza).
Briefly, 2 × 106 cells were trypsinized and resuspended in
solution with 5 μg of p-mChABC-mCherry, p-mChABC, or p-
mCherry DNA. Following transfection, cells were incubated at
37 °C with 7% CO2 and expression of the desired mChABC
protein was assessed through immunohistochemistry and the
CPC turbidity assay. The rate of cell division and transfection
efficiency were determined though immunohistochemistry.
The total number of cells was determined through Hoechst-
33342 (1:10,000; Sigma) staining, while counter staining with
Ki67 (1:200; AbCam) following cellular fixation in 4%
paraformaldehyde (Sigma) using previously defined method-
ology.29 Cells were analyzed under fluorescent microscopy
(Leica6000).
For the extraction of secreted mChABC, cells were washed
and the medium was replaced with DMEM (without phenol
red) supplemented with sodium pyruvate (1:1000) and ITS+
(1:100). The medium was collected over the following 24 h
with each sample centrifuged to remove cellular debris and
EDTA-free protease inhibitor cocktail (Roche) added to
ensure any target proteins were not cleaved by endogenous
cellular proteases. The remaining supernatant was concen-
trated (50 K centricon; Millipore) and stored at −20 °C until
required for experimentation.
CPC Turbidity Assay. Using a modified and validated form
of the CPC assay,25,29 5 μL of samples from transfected cells
was incubated with 50 μL of chondroitin sulfate A (CS-A; 20
μg; Sigma) at 37 °C for 30 min and then denatured at 95 °C.
20 μL of each sample was incubated with an equal volume of
the CPC reagent [1:1 of 0.2% (w/v) CPC and 133 mM
magnesium chloride; Fluka]. Absorbance was measured at 405
nm using a μQuant Microplate Spectrophotometer (Biotek
Instruments), and data were adjusted for baseline based on the
negative control. Addition of DNase (Thermo Fisher
Scientific) failed to alter optical density data. Using a
calibration curve generated with known quantities of bChABC
(Sigma), the quantity of the active enzyme in each sample was
determined based on the measured absorbance. Calculations
were assessed through three separate experiments where, in
each, five known concentrations of the enzyme were accurately
calculated using this methodology.29
Characterization of ChABC Activity. Enzyme activity
was defined as the amount of the product formed by an
enzyme per milligram of the total protein (μmol min−1 mg−1).
Solutions were made in 50 mM Tris−HCl (pKa = 8.06) and 50
mM NaAc buffer. This buffer was utilized in all experiments as
per manufacturers’ guidance to facilitate the activity of
bChABC (Sigma Aldrich), as it could accommodate a large
pH range.6,33 Samples of mChABC from transfected HEK293
cells (collected over 24 h) or bChABC (each 2 μL at 0.5 μg/
μL as determined through the CPC turbidity assay) were
mixed in an excess of the GAG substrate (400 μL at 1 mg/mL)
in a quartz cuvette. The cuvette was immediately placed in a
temperature-controlled spectrophotometer (Lambda 35 UV/
VS spectrometer, Perkin Elmer), and change in absorbance was
monitored every 0.2 ms for 5 min at 232 nm, a wavelength
corresponding to the absorbance of disaccharides produced
from enzymatic activity.6,33,43 Enzyme samples were kept on
ice prior to the commencement of the assay, while the
substrate was prewarmed to the temperature at which the
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experiment was conducted. A 2 μL sample of buffer solution
was assessed as a negative control. All commercial bChABC
enzymes were incubated in DMEM (without phenol red) for
24 h at 37 °C prior to analysis, so as to match the
environmental conditions of the mChABC. Quantities of all
active enzymes used were determined using the CPC turbidity
assay and protein concentration assessed by absorbance at 280
nm on the spectrophotometer.
To acquire enzyme activity, absorbance was corrected for
background based on the negative control. The rate of
absorbance change was calculated by linear regression (Prism).
This was converted to concentration and enzyme activity
assessed through Beer-Lamberts Law [rate of absorbance
change = molar absorption coefficient (ε) × concentration ×
cuvette path length], assuming that the chemical equilibrium
remained constant. ε of ChABC is 3800 M−1 cm−1,6,33,43 and
experiments were carried out at a 1 cm path length. The
protocol described was validated using Seikagaku bChABC
(not used in further experiments, as it is no longer
commercially available), and the values obtained were
consistent with those reported in the literature.4,6,33−35
To characterize mChABC activity, the enzyme was assessed
under of a variety of conditions to determine substrate
specificity, optimal pH and temperature, and enzyme kinetics.
Substrate Specificity. Determined using four GAG
substrates: CS-A from bovine trachea (Sigma), dermatan
sulfate (DS or CS-B) from porcine intestinal mucosa (Sigma),
CS-C from shark cartilage (Sigma), and hyaluronan (HA; of
medium molecular weight250 kDa) from Streptococcus
pyogenes (R&D).
Optimal pH, Temperature, and Thermostability. The
influence of pH was investigated on CS-A and HA at 37 °C
in five pHs (pH 5.0, 6.0, 7.0, 8.0, and 9.0). Optimal
temperature was assessed by varying the temperature at
which the reaction occurred on CS-A at six intervals (25, 30,
37, 40, 45, and 50 °C). To determine thermostability, the
enzyme activity on CS-A at 37 °C was measured after enzyme
preincubation for 5, 15, and 30 min at 37 and 50 °C.
Enzyme Kinetics. CS-A was dissolved at eight concen-
trations (0.0, 0.01, 0.02, 0.05, 0.1, 0.3, 0.5, and 1.0 mg/mL) in
reaction buffer at pH 8.0, and initial reaction rates were
recorded every 0.2 ms for 5 min at 37 °C. The data were
interpreted using linear regression analysis (GraphPad Prism).
The initial rate of reaction (ν0) was determined from the value
of the slope from the plot of product formation as a function of
time. This value was corrected for background based on the
negative control. By analyzing the rate of reaction change at
each substrate concentration using Michaelis−Menten equa-
tions (with Briggs−Haldane alterations; GraphPad Prism), the
components of enzyme kinetics were calculated. This includes
the maximal/limiting velocity of an enzyme, as substrate
concentration gets large (Vmax), the concentration of the
substrate leading to half-maximal velocity (Km), and the
number of substrate molecules each enzyme site converts to
product per unit time (kcat). The values of Vmax and Km were
extracted from the Hanes plot generated by monitoring the
product formation and using the equation: [S]/ν = Km/Vm +
[S]/Vm, where Km represents the substrate concentration at
half saturation and [S] the substrate concentration. kcat was
calculated using the equation Vmax = kcat × [E], where [E]
represents total enzyme concentration. From these values, the
catalytic efficiency (kcat/Km) was determined.
Statistics. Power analysis using G*Power was conducted
prior to all experiments to ensure that sample sizes used were
sufficient to yield reliable data based on known standard
deviations to determine the expected effect size, level of
acceptable significance, and type 1 error threshold (α) ≤ 0.05
and power (1 − β) ≥ 0.90. All experiments were analyzed
blind to the experimental condition, and none were excluded
based on the outcome. A minimum of three repeats were
conducted for each experiment with separate samples being
collected from independent cell culture preparations per
condition. The parameters were compared between the control
and the test group using either the one- or two-way analysis of
variance (ANOVA) with post-hoc Turkey or Bonferroni
(defined in the text; GraphPad Prism v9). Divergences were
considered significant if P < 0.05. Significance values
represented as * = P < 0.05, ** = P < 0.01, *** = P <
0.001, and **** = P < 0.0001. Data show means ± SD.
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